About
Revalia Bio was founded on the belief that the key to fixing drug development lies in the human body itself.
Founded by researchers who spent years watching promising therapies fail in clinical trials — not because the science was wrong, but because they were developed without real human data — Revalia Bio was built to close that gap.
We built the infrastructure, the network, and the software to make Human Data Trials possible at scale. Today, we partner with the world's leading pharmaceutical companies to validate drug candidates before the first human patient is enrolled.
To accelerate the development of safe, effective therapies by bringing authentic human biology into pre-clinical research.
We believe that every donated organ is an opportunity — not just to save one life through transplant, but to advance medicine for millions. Human Data For Life™.
Our Story
Biophysicist and Revalia Bio Co-Founder Greg Tietjen worked in a lab at Yale with his Co-Founder Jenna DiRito for 11 years on organ perfusion. After learning that many donated organs could not be used for transplant, the pair were committed to finding a purpose for these organs. Revalia was born from this mission to use non-transplantable organs to accelerate research. Greg and Jenna founded the company on the premise of scalable human biological data in 2023, and we have proudly been revenue-generating since day one. As one of the first organizations to work in this space, we have attracted world-class experts to join our mission. Our team includes a transplant surgeon, researchers from Brown and Johnson & Johnson, as well as developers from Google and Amazon. We were recently awarded an ARPA-H Contract (up to $26.7 Million) to advance drug development with the Human Data Stack.
Read our latest news here.Our Beliefs
At Revalia, we believe a new model of drug and device development is needed. Our goal is to partner with researchers to shift how drugs and devices are tested because failure is unacceptable.
We believe that data integrity is an ethical obligation, and integrated human data can provide better patient relevance than traditional approaches. Revalia provides such data through the gift of organ donation.
At Revalia, we utilize donated human organs, enabling researchers to accelerate science with decision-level insights that ensure patient safety. We can deliver on our mission to honor the legacy of every donor by turning the loss of one life into knowledge that shapes the future of medicine.